Delivery Order SPE2DB22D3009-SPE2DB25FBD28
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,581.62 to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 15, 2025, and represents a non-set-aside procurement. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania serves as the place of performance for this medical supply delivery. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,790.80 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price delivery order, issued on August 8, 2025, with an ultimate completion date of August 29, 2025, represents a competitive award with no set-aside designation. The award was fulfilled by AmerisourceBergen's Corporate Office located in Conshohocken, Pennsylvania, the...
- The Defense Logistics Agency awarded a delivery order valued at $8,895.79 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-competed, firm fixed-price delivery order has a completion date of August 8, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product commonly used for post-exposure prophylaxis. This firm fixed price delivery order, valued at $10,744.80, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 through December 2026. The contract was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, valued at $1,039.53 under a firm fixed price contract type. The contract was competitively awarded without set-aside designation and is scheduled for completion by August 19, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract action under the company's...
- The Defense Logistics Agency awarded a $10,744.80 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract includes no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $5,372.40 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,744.80 on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL vials (5mL) to support federal medical procurement needs. The award is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 20, 2025, and is funded through the Defense Logistics Agency's Medical Supply Chain division. This contract represents...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for HYPERRAB 300 Unit/mL, a rabies immunoglobulin product, with a ceiling value of $18,711.54. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under a child contract...
- The Defense Logistics Agency awarded a $16,632.48 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/ML Vial medication. This firm fixed price contract, with an ultimate completion date of August 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBD28Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,197.65 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial, a rabies immunoglobulin product, with performance in Conshohocken, Pennsylvania. This competitively awarded, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation and is scheduled for completion by September 5, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains. This delivery order for rabies immunoglobulin reflects the company's ongoing role in providing specialized medical commodities to support defense healthcare programs globally under the DLA's Pharmaceutical Prime Vendor program structure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 8/14/25 |